TheLaughingStock
Member
According to the documents the latest of which is dated June 1 the working group focused on the following principles and talking points:
1. Extending the patent life of drugs in foreign markets to provide for protection and enforcement of intellectual property rights. This will ensure that American consumers do not unfairly subsidize research and development for people throughout the globe.
Extending monopoly protections for drugs overseas has been one of the pharmaceutical industrys top priorities since the Trans-Pacific Partnership was defeated last year.
That policy would push up global drug prices, according to Médecins Sans Frontières.
So, protectionism is ok but only if its costs are massive and on behalf of big business. And now that trade deals like the TPP have been defeated, this means industry is trying to find other ways to protect themselves and benefit handsomely at the expense of hundreds of millions of people. Got it.